Navigation Links
GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
Date:11/10/2008

densed Consolidated Balance Sheet Information

(amounts in thousands)

(unaudited)

Sep. 30, Dec. 31,

2008 2007

Assets:

Cash and cash equivalents $2,785 $1,990

Other current assets 578 1,041

Total current assets 3,363 3,031

Property, net 127 75

Other assets 368 140

Total assets $3,858 $3,246

Liabilities and stockholders' equity

Current liabilities $516 $598

Stockholders' equity 3,342 2,648

Total liabilities and stockholders' equity $3,858 $3,246

Shares Outstanding 743,415 731,628

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's HIV/AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax HIV/AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax HIV/AIDS vaccines also may be effective as therapeutics (treatment of people already infected with AIDS virus). Studies evaluating these vaccines in HIV/AIDS infected individuals are in the planning stage.

GeoVax's core HIV/AIDS vaccine technologies were developed through a collaboration of colleagu
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/22/2014)... Memphis, TENN (PRWEB) December 22, 2014 ... with Donor Egg Bank USA , a network ... the country. Through this partnership, patients have fast access ... for in vitro fertilization, IVF . Fertility Associates of ... to offer this fertility treatment option. , Dr. ...
(Date:12/19/2014)... 19, 2014 Charm Sciences is pleased ... the Detection of Aflatoxin M1 in raw commingled milk ... third party validation. The peer reviewed report of the ... Institute for Agricultural and Fisheries Research (ILVO-T&V) has been ... Aflatoxin B1, the most toxic aflatoxin and a known ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... encouraging other companies across the country to hold their events ... to bring their helping hearts and hands, LEXINGTON, Mass., ... held in New Orleans for the first time, Indevus,Pharmaceuticals (Nasdaq: ... is dispatching 125 sales representatives to the,1900 and 2000 blocks ...
... SUNRISE, Fla., March 20 Bioheart, Inc.,(Nasdaq: BHRT ) ... after the close of the market on Thursday, March 27, ... 27, 2008 at,4:30 p.m. Eastern to discuss these results., ... or,(706) 643-0580, or can listen via a live Internet web ...
... N.J., March 20 Pharmacopeia,(Nasdaq: PCOP ), an ... therapeutics, today announced that Dr. Leslie J. Browne,President and ... 15TH Annual Future Leaders in the Biotech Industry,Conference. The ... Millennium,Broadway Hotel & Conference Center in New York, NY., ...
Cached Biology Technology:125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 2125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 3125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008 2Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 2Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 3Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... open farmland, wooded "shade" plantations that produce coffee and chocolate ... study says forests remain the best habitat for tropical birds. ... and "agroforests" where crops are grown under trees ... of various types of birds may hurt "ecosystem services" that ...
... estimates, a third of Earth,s organisms live in our planet,s ... mystery. This week, the work of microbiologist James Holden ... into this dark world. In the journal Proceedings ... the first detailed data on methane-exhaling microbes that live deep ...
... of Nursing,s (NYUCN) Joyce K. Anastasi, PhD, DrNP, FAAN, ... of the Division of Special Studies in Symptom Management ... National Institutes of Health (NIH) grant for the study ... The primary aim of the study ...
Cached Biology News:Birds do better in 'agroforests' than on farms 2Birds do better in 'agroforests' than on farms 3Birds do better in 'agroforests' than on farms 4Birds do better in 'agroforests' than on farms 5Scientists define new limits of microbial life in undersea volcanoes 2Scientists define new limits of microbial life in undersea volcanoes 3NYU College of Nursing's Dr. Anastasi awarded $2.5 million from NIH to study IBS symptom management 2
... DNA Polymerase is a premium quality recombinant ... thermostable enzyme is suitable for a wide ... highest purity and reproducible performance, each preparation ... quality control assays. NovaTaq DNA Polymerase possesses ...
... cell sorter sets a new standard for ... a revolutionary new design in instrumentation, this ... multicolor analysis. The BD FACSAria instrument is ... fixed-alignment cuvette flow cell. This new ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Biology Products: